CJC-1295/Ipamorelin Blend 5mg/5mg is a dual-peptide research formulation containing 5mg CJC-1295 NO DAC and 5mg Ipamorelin, for a total peptide content of 10mg per vial.
This research blend combines two compounds studied through distinct but complementary growth hormone signaling pathways. CJC-1295 NO DAC is associated with growth hormone-releasing hormone (GHRH) receptor research, while Ipamorelin is a synthetic growth hormone secretagogue studied primarily in relation to the ghrelin/growth hormone secretagogue receptor (GHS-R1a).
The combination provides researchers with a single formulation for investigating interactions between GHRH-mediated and ghrelin-receptor-mediated signaling within controlled laboratory models.
CJC-1295/Ipamorelin Blend is supplied strictly for laboratory research and analytical investigation. It is not intended for human or animal consumption, clinical use, diagnostic use, therapeutic use, or veterinary use.
Research Specifications
|
|
| Product Name |
CJC-1295/Ipamorelin Blend |
| Total Peptide Content |
10mg |
| CJC-1295 NO DAC |
5mg |
| Ipamorelin |
5mg |
| Form |
Lyophilized Powder |
| Research Classification |
Dual-Peptide Research Blend |
| Primary Research Pathways |
GHRH & GHS-R1a Signaling |
| CJC-1295 NO DAC Target |
GHRH Receptor |
| Ipamorelin Target |
Growth Hormone Secretagogue Receptor (GHS-R1a) |
| Intended Use |
Laboratory Research Only |
Dual-Pathway Growth Hormone Research
CJC-1295 NO DAC and Ipamorelin have been investigated through different signaling mechanisms associated with growth hormone regulation.
CJC-1295 NO DAC is studied as a modified GHRH-related peptide. GHRH signaling occurs through the growth hormone-releasing hormone receptor and represents an important stimulatory component of growth hormone regulation.
Ipamorelin belongs to the growth hormone secretagogue class and has been investigated as an agonist of GHS-R1a, commonly known as the ghrelin receptor.
Combining these research compounds provides a model for investigating two separate receptor systems associated with growth hormone signaling within the same experimental framework.
CJC-1295 NO DAC Research
CJC-1295 NO DAC is commonly associated with a 29-amino-acid modified GHRH fragment used in laboratory investigation of GHRH receptor signaling.
Activation of the GHRH receptor initiates intracellular signaling associated with growth hormone synthesis and secretion. Modified GHRH-related peptides therefore provide researchers with tools for investigating receptor activity, signaling dynamics, and downstream components of the growth hormone axis.
The NO DAC designation distinguishes this research material from DAC-modified CJC-1295. The non-DAC form does not contain the Drug Affinity Complex designed to facilitate albumin binding and extend the persistence of CJC-1295 DAC.
Ipamorelin Research
Ipamorelin is a synthetic peptide belonging to the growth hormone secretagogue class.
It has been studied primarily in relation to the growth hormone secretagogue receptor type 1a (GHS-R1a). This receptor is also the principal signaling receptor associated with ghrelin.
Experimental research has characterized Ipamorelin as a selective growth hormone secretagogue, making it useful for studying ghrelin-receptor signaling and mechanisms associated with growth hormone release.
Its signaling mechanism is distinct from the GHRH receptor pathway investigated with CJC-1295 NO DAC.
GHRH & GHS-R1a Signaling Research
One of the principal research interests surrounding a CJC-1295/Ipamorelin blend is the ability to investigate GHRH receptor and GHS-R1a signaling simultaneously.
Although both pathways participate in growth hormone regulation, they operate through different receptors and signaling mechanisms.
This makes the combination useful in experimental models examining receptor interactions, secretory signaling, neuroendocrine regulation, and downstream components of the growth hormone/IGF-1 axis.
Research involving these pathways remains experimental and should not be interpreted as establishing therapeutic or clinical effects.
Molecular Research Profile
CJC-1295/Ipamorelin Blend contains two distinct synthetic peptides rather than a single molecular compound. As a result, the finished blend does not have one molecular formula, molecular weight, amino-acid sequence, or CAS number.
Each component maintains its own molecular identity.
CJC-1295 NO DAC terminology has also historically been used inconsistently across research and commercial sources. Exact molecular identifiers for that component should therefore be matched to the chemical identity specified by applicable batch documentation.
Ipamorelin is a separate synthetic pentapeptide with its own defined molecular characteristics.
For research blends, analytical specifications should be interpreted according to the individual components and applicable batch-specific documentation rather than assigning a single molecular identifier to the combined formulation.
Lyophilized Research Peptide Blend
CJC-1295/Ipamorelin Blend 5mg/5mg is supplied in lyophilized powder form for laboratory research.
Lyophilization removes water from the material under controlled conditions, producing a stable dry research format suitable for storage and subsequent laboratory preparation according to established research protocols.
Batch-specific analytical documentation may be available to provide additional information regarding the identity and purity of the research material.
Research Use Only
CJC-1295/Ipamorelin Blend 5mg/5mg is intended strictly for laboratory research purposes only.
This product is not intended for human consumption, animal consumption, clinical use, diagnostic use, therapeutic use, veterinary use, or for the treatment, cure, mitigation, or prevention of any disease.
